Phase II study of 1,2,4-triglycidylurazol (TGU) in previously untreated and treated patients with small cell lung cancer.
Six previously untreated poor prognosis patients and eight previously treated patients with small cell lung cancer (SCC) were treated with 1,2,4-triglycidylurazol (TGU, NSC-332488) 800 and 650 mg/m2 every 4 weeks, respectively. No responses were observed. The survival time of the previously untreated patients was short, a median of 7 weeks (range 5-10 weeks). Myelosuppression was severe and prolonged with white blood count, WHO grade 3-4, in four previously untreated patients and in two previously patients, and with platelets, WHO grade 3-4, in both four previously untreated and in four previously treated patients. Gastrointestinal toxicity was mild to moderate. It is concluded that TGU is inactive in SCC.
Lund
B
B
Department of Internal Medicine C, Bispebjerg Hospital, Copenhagen, Denmark.
Hansen
F
F
Hansen
M
M
Hansen
H H
HH
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011379:Prognosis; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014230:Triazoles; C041113:anaxirone